Latest Content

Two and a half years into cancer treatment, my nurse Jenny Gnoza still greets me with a smile, steadies my nerves and finds the vein everyone else misses.

AI is changing breast cancer screening, helping doctors detect cancer and predict future risk. Learn what AI mammography means for patients.

FDA grants accelerated approval to camizestrant for certain advanced breast cancers with ESR1 mutations, offering a new treatment option.

Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone.

One prostate cancer combination is awaiting an FDA decision this year, and several late-stage trials could produce the next filings. Here's what to watch.

Learn what patients should know about thyroid cancer treatment, including surgery, radioactive iodine, surveillance, hormone replacement and new advances.

Jen Christensen, RN, BSN, MSN, of City of Hope Orange County, brings deep personal experience with cancer loss to her role as a nurse manager, combining clinical excellence with compassionate, family-centered care.

Former NFL linebacker Chris Draft honors his late wife Keasha by advocating for lung cancer research and equitable access to care.

Four breast cancer treatments are awaiting FDA decisions, with two due before the end of 2026. Here's what's under review, what the data show and what it means.

NEJM-published phase 1/2 data show RASONQUE achieved a 42% response rate and 89% disease control in RAS mutant metastatic lung cancer.

In the phase 3 CERVINO trial, etentamig improved response rates and progression-free survival compared with standard therapies in patients with relapsed/refractory multiple myeloma.

Gail Fackler reflected on her husband Jim’s stage 4 small cell lung cancer diagnosis, the uncertainty they faced and the hope they found through a clinical trial.

Dr. Jenni Sheng discussed weight management after breast cancer, when medication may be considered and why survivorship care goes beyond cancer surveillance.